STANDARD OPERATING PROCEDURE
|
|
- Ashlie Charla Kelly
- 5 years ago
- Views:
Transcription
1 STANDARD OPERATING PROCEDURE Title Reference Number Site Initiation SOP-RES-010 Version Number 2 Issue Date 15 Apr 2016 Effective Date 26 May 2016 Review Date 26 May 2018 Author(s) Reviewer(s) Rachelle Ward, Research Project Manager Teresa O Leary, Head of Regulatory Compliance Authorisation (Original signatures are retained by Research & Innovation) Dr Stephen Ryder Director of Research & Innovation Dr Stephen Fowlie Medical Director 04 Apr Apr 2016 USERS OF THIS STANDARD OPERATING PROCEDURE MUST REFER TO TO ENSURE THE MOST CURRENT VERSION IS BEING USED
2 Page 2 of 8 1. Document History Version Issue Date Reason for Change Number 1 22 nd April 2014 Original SOP. It replaces SOP Apr 2016 Biennial review and inclusion of HRA approval
3 Page 3 of 8 2. Introduction The Research and Innovation (R&I) department, which acts on behalf of the sponsor for Nottingham University Hospitals NHS Trust (NUH), is responsible for putting in place the necessary procedures to secure the quality of every aspect of a clinical study including clinical study activities carried out by institutions and investigators participating in studies sponsored by NUH. Site initiation visits (SIVs) occur prior to site activation for a specific protocol. These visits have several goals: to orient and train staff on the protocol and study related processes; to confirm readiness for study implementation; and to identify additional requirements that must be satisfied prior to site activation and participant recruitment. 3. Purpose and Scope This standard operating procedure (SOP) outlines the SIV process for all clinical trials of investigational medicinal products (CTIMPs), clinical investigations of medical devices (CMDs) and gene therapy studies that are sponsored by NUH. Other studies (which are not a CTIMP or CMD) but also require an SIV (in accordance with the risk assessment outcome, SOP-RES-002 Risk Assessment) fall under the scope of this procedure. Studies can be single- or multi-site investigator-led and the SIV can be performed on-site or remotely. An SIV is required to prepare and set up a research site to conduct a study. The SIV will be scheduled according to the Monitoring Plan (MP) (TAFR00202) and must take place before the site can be given the green light (refer to SOP-RES-011 Site Green Light) to commence recruitment. 4. Responsibilities Sponsor (fulfilled by the Research and Innovation (R&I) department on behalf of NUH) The Head of Regulatory Compliance (HRC) and/or QA/GCP Auditor (QAA) will implement the Monitoring Plan (MP) based on the outcome of the risk assessment. The Research Project Manager (RPM) will undertake the SIV according to the MP. Chief Investigator (CI)
4 Page 4 of 8 Study specific elements of the SIV are delegated to the CI as outlined in the agreement and SIV agenda. 5. Definitions CA CI CMD CTIMP GCP Green Light HRA HRC IMP ISF MHRA NHS NUH PI QA QAA R&D R&I RPM SIV SOP SRM TMF Competent Authority, in the United Kingdom this is the MHRA Chief Investigator Clinical Investigation of a Medical Device Clinical Trial of an Investigational Medicinal Product Good Clinical Practice Sponsor authorisation for the site to commence recruitment; issued after the site has received all other approvals and HRA approval Health Research Authority Head of Regulatory Compliance Investigational Medicinal Product Investigator Site File Medicines and Healthcare products Regulatory Agency National Health Service Nottingham University Hospitals NHS Trust Principal Investigator Quality Assurance QA/GCP Auditor Research and Development Research and Innovation Research Project Manager Site Initiation Visit Standard Operating Procedure Senior Research Manager Trial Master File
5 Page 5 of 8 6. Procedure When HRA and all regulatory approvals are in place, and the host NHS organisation has confirmed their capacity to conduct the study, the RPM will arrange the SIV. The SIV should include a visit to the site pharmacy to discuss the Investigational Medicinal Product (IMP) management (for studies involving drugs). A study cannot commence in the NHS in England until HRA Approval has been issued Recruitment must not commence at the site until the sponsor has explicitly given authorisation ( green light ) for it to do so. A summary of the SIV process is provided in Appendix Preparation for the Site Initiation Visit The RPM will contact the CI/Principal Investigator (PI) and study Pharmacist (for studies involving drugs) to schedule the date, time and location of the SIV ensuring that it is as close to the HRA approval date as possible. It is essential that all relevant study team members identified by the CI/PI attend the SIV. Representatives from support departments should also attend if necessary (e.g. radiology and pathology). The RPM will send the PI the Site Initiation Confirmation Letter (TAFR01004) and Site Initiation Visit Agenda (TAFR01001) giving as much notice as possible. A copy of both will be sent to the CI. Prior to the SIV the RPM will ensure that the Trial Master File (TMF) has been set up according to regulatory and sponsor requirements (refer to SOP-RES-014 Maintaining Study Files). Any missing documents can be collected from- or provided to- the site during the SIV. 6.2 During the Site Initiation Visit The RPM will ask all members who attend the SIV to sign the Site Initiation Visit Attendance Log (TAFR01002). All aspects of the agenda must be covered in the SIV. The agenda may be restructured during the SIV to allow for research staff and facility availability. Any aspect of the agenda not covered in the SIV must be documented and may need to be covered at another date and time. The RPM will confirm this with the site as per 6.1.
6 Page 6 of 8 The RPM will use the Site Initiation Report (TAFR01003) template to document the SIV. 6.3 Post Site Initiation Visit The site initiation report and Site Initiation Follow-up Letter (TAFR01005) should be prepared by the RPM and reviewed by the Head of Regulatory Compliance (HRC) or Senior Research Manager (SRM) within 10 working days of the SIV. If any areas identified during the SIV require further clarification or any document anomalies need to be reconciled then these will be listed in the follow-up letter and the site may not be authorised to commence recruitment. A copy of the site initiation report and follow-up letter along with any supporting documents will be sent to the site PI and a copy sent to the CI. The original, signed site initiation report should be filed within the TMF and a copy filed in the Investigator Site File (ISF). The site will be authorised to commence recruitment once they receive the sponsor s green light. If the site has no outstanding actions following the SIV the RPM will issue the green light at the same time as the SIV follow-up letter. If the site had actions to address as identified in the SIV follow-up letter the sponsor s green light will only be issued once evidence has been provided to the RPM that all queries have been resolved. If the site fails to address outstanding actions from the SIV in a timely manner the RPM will escalate this to the Head of Regulatory Compliance or Senior Research Manager who will liaise with the site (and the CI) to complete the actions or to consider withdrawing the site from the study. Subsequent monitoring of the investigator site will occur at an agreed frequency according to the MP (refer to SOP-RES-013 Monitoring). 6.4 Remote Site Initiation Visit A site may be selected for a remote initiation as documented in the MP. The SIV will be confirmed as per 6.1. The RPM will provide an electronic copy of the Site Initiation Visit Attendance Log (TAFR01002) for the site to sign which should be returned to the RPM after the SIV. The SIV will be conducted either by teleconference or another remote communication method. The remote SIV will be followed up in the same manner as if it were conducted on-site (as per 6.2 and 6.3).
7 Page 7 of 8 7. References The Medicines for Human Use (Clinical Trials) Regulations 2004 and subsequent amendments International Conference on Harmonisation Guidelines for Good Clinical Practice E6 (R1) ISO Clinical Investigation of Medical Devices for Human Subjects TAFR00202 TAFR01001 TAFR01002 TAFR01003 TAFR01004 TAFR01005 TAFR01102 SOP-RES-002 SOP-RES-006 SOP-RES-011 SOP-RES-013 SOP-RES-014 Monitoring Plan Site Initiation Visit Agenda Site Initiation Visit Attendance Log Site Initiation Report Site Initiation Confirmation Letter Site Initiation Follow Up Letter Green Light Approval Letter Risk Assessment Local Assess, Arrange and Confirm Process Site Green Light Monitoring Maintaining Study Files 8. Appendices
8 Page 8 of 8 Appendix 1. Site Initiation Visit Process HRA Approval in place and site have confirmed capacity to conduct the study Arrange SIV Send SIV Confirmation Letter and SIV Agenda to site Site Initiation Visit SIV Report Outstanding actions SIV follow-up letter and SIV report sent to site along with supporting documentation No outstanding actions Green light approval letter sent to site Recruitment can commence at site
STANDARD OPERATING PROCEDURE SOP 720 RISK ASSESSMENT OF TRIALS SPONSORED. BY THE NNUH and UEA
STANDARD OPERATING PROCEDURE SOP 720 RISK ASSESSMENT OF TRIALS SPONSORED BY THE NNUH and UEA Version 1.0 Version date 13.12.2016 Effective date 13.12.2016 Number of pages 11 pages Review date November
More informationAnnual Progress and Safety Reporting SOP for HEY-sponsored CTIMPs
R&D Department Annual Progress and Safety Reporting SOP for HEY-sponsored CTIMPs Hull and East Yorkshire Hospitals NHS Trust 2010 All Rights Reserved No part of this document may be reproduced, stored
More informationNEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES
SOP details SOP title: SOP number: SOP category: Version number: 03 Version date: 19 December 2016 Effective date: 19 January 2017 Revision due date: 19 January 2020 NEWCASTLE CLINICAL TRIALS UNIT STANDARD
More informationSOP-QA-30 V Scope
Title: Effective Date: 1-4-17 Review Date: 1-4-20 Author: Joanne Rodger, Senior R&D Manager QA Approval: Richard Cowie, QA Manager Approver: Prof Maggie Cruickshank, R&D Director Approver: Prof Steve Heys,
More informationStandard Operating Procedure CPFT/SOP003 Serious Breach of Protocol or GCP in CTIMPs
Standard Operating Procedure CPFT/SOP003 Serious Breach of Protocol or GCP in CTIMPs Author: Sponsor/Executive: Responsible committee: Ratified by: Consultation & Approval: (Committee/Groups which signed
More informationStandard Operating Procedure Research Governance
Queen s University Belfast Research and Enterprise Standard Operating Procedure Research Governance Title: Application to MHRA for Clinical Trials Authorisation SOP Reference QUB-ADRE-OlO Date prepared
More informationStandard Operating Procedures (SOP) Research and Development Office
Standard Operating Procedures (SOP) Research and Development Office Title of SOP: GCP Inspection Procedures (MHRA) SOP Number: 15 Version Number: 2.0 Supercedes: 1.0 Effective date: August 2013 Review
More informationResearch & Development. J H Pacynko and J Illingworth. Research, pharmacy and R&D staff
Department Title of SOP Research & Development Safety reporting SOP SOP reference no: R&D GCP SOP 07 Authors: Current version number and date: J H Pacynko and J Illingworth Version 9, 31.01.18 Next review
More informationSTANDARD OPERATING PROCEDURE
Research Department STANDARD OPERATING PROCEDURE SOP Number C117 Version Number 1.3 Effective Date Author Anna Leesley Angela Pinder Related SOPs C108: Sponsorship C109: Code Break B131: Monitoring of
More informationInformed Consent Procedures and Writing Informed Consent Forms
STANDARD OPERATING PROCEDURE Informed Consent Procedures and Writing Informed Consent Forms Standard Operating Procedure Western Health SOP reference 006 Version: 2.0 dated December 2015 Effective Date
More informationSTANDARD OPERATING PROCEDURE
Research Department STANDARD OPERATING PROCEDURE SOP Number C117 Version Number 2.1 Effective Date 01 Sept 2018 Author Angela Pinder Related SOPs C108: Sponsorship C109: Code Break C118: Risk Assessment
More informationPATIENT GROUP DIRECTION PROCEDURE
PATIENT GROUP DIRECTION PROCEDURE Date approved 2 October 2015 Version 3 Approved by Yvette Oade, Chief Medical Officer Procedure Lead Clinical Governance Lead - Medicines Management Procedure Author Karen
More informationChief Dental Officer England: Advice on commercial practice of online registered dental practitioners selling patient group directions for NHS
Chief Dental Officer England: Advice on commercial practice of online registered dental practitioners selling patient group directions for NHS England commissioned services. Chief Dental Officer England:
More informationUNIVERSITY OF LEICESTER, UNIVERSITY OF LOUGHBOROUGH & UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST JOINT RESEARCH & DEVELOPMENT SUPPORT OFFICE
UNIVERSITY OF LEICESTER, UNIVERSITY OF LOUGHBOROUGH & UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST JOINT RESEARCH & DEVELOPMENT SUPPORT OFFICE STANDARD OPERATING PROCEDURES University of Leicester (UoL)
More informationUKALL14 DRUG SUPPLY GUIDELINES
CONTACT DETAILS UKALL14 DRUG SUPPLY GUIDELINES For further information on trial drugs, trial protocol, dosing, supply drug and distribution queries please contact: UKALL14 Trial Team Phone: 0207 679 9860
More informationPatient Group Directions Policy
Patient Group Directions Policy Category: Summary: Equality Analysis undertaken: Valid From: Date of Next Review: Approval Date/ Via: Distribution: Related Documents: Author(s): Further Information: This
More informationStandard operating procedure
Standard operating procedure Title: Preparation of an initial European Public Assessment Report (EPAR) for a human medicinal product following positive or negative opinion Status: PUBLIC Document no.:
More informationCase scenarios: Patient Group Directions
Putting NICE guidance into practice Case scenarios: Patient Group Directions Implementing the NICE guidance on Patient Group Directions (MPG2) Published: March 2014 [updated March 2017] These case scenarios
More informationPharmacy Manual. Cambridge University Hospitals NHS Foundation Trust & University of Cambridge
Page 1 of 11 Pharmacy Manual Trial Title: PRedicting Outcomes For Crohn s disease using a molecular biomarker (PROFILE) trial EudraCT Number: N/A (non-ctimp study) ISRCTN: 11808228 REC Reference: 17/EE/0382
More informationStandard operating procedure
Standard operating procedure Title: Early Notification System: procedure for advanced notification of emerging safety issues to EU regulatory network and international partners Status: PUBLIC Document
More informationTrust Policy 218 Ionising Radiation Safety Policy
Trust Policy 218 Ionising Radiation Safety Policy Purpose Date Version August 2016 7 To ensure that Plymouth Hospitals NHS Trust complies with all relevant legislation with regard to the use of ionising
More informationPatient Group Directions (PGDs)
Patient Group Directions (PGDs) Document level: Trustwide (TW) Code: MP2 Issue number: 4 Lead executive Authors details Type of document Target audience Document purpose Medical Director Senior Clinical
More informationPolicy and Procedure for the Development, Approval and Implementation of Patient Group Directions in NHS Haringey Clinical Commissioning Group
BEFORE USING THIS POLICY ALWAYS ENSURE YOU ARE USING THE MOST UP TO DATE VERSION Policy and Procedure for the Development, Approval and Implementation of Patient Group Directions in NHS Haringey Clinical
More informationl Chief Investigator/R & D Committee member
North Staffordshire Combined Healthcare '~l:~j Breach of Protocol or Good Clinical Practice SOP Reference R&D-SOP-SOS-002 Version Number Effective Date 19'" February 2010 Review Date 18 m February 2012
More informationPATIENT GROUP DIRECTIONS POLICY
PATIENT GROUP DIRECTIONS POLICY To be read in conjunction with the Medicines Policy and the Controlled Drugs Policy Version: 5 Ratified by: Senior Managers Operations Group Date ratified: August 2015 October
More informationMHRA Pharmacovigilance Inspections: Prepare and Manage for Success
MHRA Pharmacovigilance Inspections: Prepare and Manage for Success Created and Presented by Miranda Dollen Vice President, Pharmacovigilance & EEA QPPV Mapi 2016, All Rights Reserved 2 Prepare and Manage
More informationSPIRIT 2 Investigator Site File Checklist Generic Documents
SPIRIT 2 Investigator Site File Checklist Generic Documents Section Section name Document 1.0 Site file S2 ISF Table of Contents v2.0 (13 February 2012) S2 Documentation Version Control v22 (12 Mar 2018)
More informationDeveloped By Name Signature Date
Patient Group Direction 2155 version 2.0 Administration / Supply of Inhaled Salbutamol in Asthma by Registered Practitioners employed by Torbay and South Devon NHS Foundation Trust Date of Introduction:
More informationINITIATION SLIDES VERSION
PARADIGM- 2 (BR36) OlaPArib and RADIotherapy or olaparib and radiotherapy plus temozolomide in newly-diagnosed Glioblastoma stratified by MGMT status: 2 parallel phase I studies INITIATION SLIDES VERSION
More informationStandard Operating Procedure:
Standard Operating Procedure: Name of procedure: Taking Informed Consent SOP Number: SOP07/UoE/HTA (includes Adverse Events Reporting Form) Version Number & Date: V5 16/01/2017 Review Date: Annually Superseded
More informationNATIONAL DENTAL INSPECTION PROGRAMME
1. Purpose of Paper NATIONAL DENTAL INSPECTION PROGRAMME This paper describes the main components and processes associated with the National Dental Inspection Programme (NDIP) and demonstrates how the
More informationTuesday 6 th November Second Floor Hemel One Boundary Way Hemel Hempstead HP2 7YU
Tuesday 6 th November 2018 Mr Seamus Quilty Chairman HCC Health Scrutiny Committee Dear Seamus Second Floor Hemel One Boundary Way Hemel Hempstead HP2 7YU 01442 898 888 www.hertsvalleysccg.nhs.uk Herts
More informationCAUTION: Refer to the Document Library for the most recent version of this policy. Policy for the use of Cytomegalovirus (CMV) negative blood products
Directorate Department Year Version Number Central Index Number Endorsing Committee Date Endorsed Approval Committee Date Approved Author Name and Job Title Key Words (for search purposes) Date Published
More informationUSE OF UNLICENSED MEDICINES AND OFF-LABEL MEDICINES WHERE A LICENSED MEDICINE IS AVAILABLE
NHS Scotland Directors of Pharmacy and Scottish Association of Medical Directors USE OF UNLICENSED MEDICINES AND OFF-LABEL MEDICINES WHERE A LICENSED MEDICINE IS AVAILABLE CONSENSUS STATEMENT This consensus
More informationTERMS AND CONDITIONS NATIONAL GOOD LABORATORY PRACTICE (GLP) COMPLIANCE MONITORING AUTHORITY
TERMS AND CONDITIONS OF NATIONAL GOOD LABORATORY PRACTICE (GLP) COMPLIANCE MONITORING AUTHORITY FOR OBTAINING AND MAINTAINING ITS GLP CERTIFICATION BY A TEST FACILITY Document No.GLP-101 Version/Issue
More informationSafeguarding Children and Young People Policy
Safeguarding Children and Young People Policy Policy Summary This policy outlines our commitment to keeping the children and young people who engage with the Red Cross safe. It outlines the expectations
More informationGuidance on Bulk Prescribing for Care Home Patients
Guidance on Bulk Prescribing for Care Home Patients Introduction Many patients in care homes taking medicines when required (PRN) can inevitably present problems for the prescriber in determining the quantity
More informationNewcastle Safeguarding Children Board Business Group Terms of Reference
Newcastle Safeguarding Children Board Business Group Terms of Reference 1. Purpose Newcastle Safeguarding Children Board (NSCB) Business Group will act as the executive business group on behalf of Newcastle
More informationDATA MONITORING COMMITTEE & TRIAL STEERING COMMITTEE CHARTERS
DATA MONITORING COMMITTEE & TRIAL STEERING COMMITTEE CHARTERS DOCUMENT NO.: CR015 v1.0 AUTHOR: Lorn Mackenzie ISSUE DATE: 31 January 2017 EFFECTIVE DATE: 14 February 2017 1 INTRODUCTION 1.1 The Academic
More informationSchools Hearings & Appeals Procedure
Schools Hearings & Appeals Procedure Status: Updated October 2016. The following procedures will apply when cases are referred to Hearings and Appeals; Contents: Page Hearings 2 Appeals 2 The role of HR
More informationFencino patch (5) 2. Check the practice has agreed to the protocol and a signed copy is in place.
Switch protocol: Fentanyl/Durogesic patches to Fencino /Matrifen /Mezolar brand switch Applies to HaRD CCG employed Pharmacists and Medicines Optimisation Technicians. These protocols are produced by the
More informationMHRA Pharmacovigilance System Master File (PSMF) Inspection Findings
MHRA Pharmacovigilance System Master File (PSMF) Inspection Findings Gretel Sakyi Medical Information and Patient Safety Manager AstraZeneca UK 07 June 2018 Agenda MHRA inspections How inspectors use the
More informationStandard Operating Procedure: Early Intervention in Psychosis Access Times
Corporate Standard Operating Procedure: Early Intervention in Psychosis Access Times Document Control Summary Status: New Version: V1.0 Date: Author/Owner: Rob Abell, Senior Performance Development Manager
More informationPROCEDURE REFERENCE NUMBER SABP/EXECUTIVE BOARD/0017/PROCEDURE15 PROCEDURE NAME MEDICINES PROCEDURE 15: METHOTREXATE
PROCEDURE REFERENCE NUMBER SABP/EXECUTIVE BOARD/0017/PROCEDURE15 PROCEDURE NAME MEDICINES PROCEDURE 15: METHOTREXATE BRIEF OUTLINE OF THIS PROCEDURE This procedure sets out the requirements for prescribing,
More informationCommunity Pharmacy Enhanced Service. Just In Case 4 Core Drugs supply. Stock Holding of Palliative Care Medicines
Community Pharmacy Enhanced Service Just In Case 4 Core Drugs supply Stock Holding of Palliative Care Medicines Parties to the Agreement Provider: Purchaser: NHS Blackpool 1. Service description 1.1 This
More informationMetformin MR to low cost branded generic (Sukkarto SR) Switch Protocol
Metformin MR to low cost branded generic (Sukkarto SR) Switch Protocol Applies to HaRD CCG employed Pharmacists and Medicines Optimisation Technicians. These protocols are produced by the NY&AWC MM team
More informationCABINET PROCURING A SUBSTANCE MISUSE & COMMUNITY TREATMENT SERVICE IN RUTLAND
CABINET Report No: 105/2017 PUBLIC REPORT 16 May 2017 PROCURING A SUBSTANCE MISUSE & COMMUNITY TREATMENT SERVICE IN RUTLAND Report of the Director of Public Health Strategic Aim: Safeguarding Key Decision:
More informationTITLE: Obtaining Informed Consent of Non-English Speakers SOP #: CON-101 (formerly SM-507) Page: 1 of 7 Effective Date: 1/14/2016
SOP #: CON-101 (formerly SM-507) Page: 1 of 7 Effective Date: 1. POLICY STATEMENT: All informed consent information (initial or updates for new information) must be presented in a language that is understandable
More informationAsacol / Mesalazine to Octasa Switch protocol
Asacol / Mesalazine to Octasa Switch protocol Applies to HaRD MMT Technicians, Pharmacists These protocols are produced by the NY&AWC MM team hosted by HaRD CCG for use by their employed MM team members.
More informationTrust Policy. Control of Smoking Policy (Patients and Visitors)
Trust Policy Control of Smoking Policy (Patients and Visitors) Purpose Date May 2016 Version V3 Final To discharge the Trust s responsibilities under the Health Act 2006, and associated NICE Guidelines
More informationGOVERNING BODY MEETING in Public 22 February 2017 Agenda Item 3.4
GOVERNING BODY MEETING in Public 22 February 2017 Paper Title Purpose of paper Redesign of Services for Frail Older People in Eastern Cheshire To seek approval from Governing Body for the redesign of services
More informationSpecialised Services Commissioning Policy. CP29: Bariatric Surgery
Specialised Services Commissioning Policy CP29: Bariatric Surgery Document Author: Specialist Planner, Cardiothoracic Executive Lead: Director of Planning Approved by: Management Group Issue Date: 12 June
More informationHow to change the legal classification of a medicine in New Zealand
How to change the legal classification of a medicine in New Zealand Guidance document Medsafe October 2017 Page 1 of 15 Contents Purpose and scope... 3 Definitions... 3 Background and legislative context...
More informationPRIMARY CARE CO-COMMISSIONING COMMITTEE 18 March 2016
Part 1 Part 2 PRIMARY CARE CO-COMMISSIONING COMMITTEE 18 March 2016 Title of Report Supporting deaf patients to access primary care services Purpose of the Report The report is to provide the co-commissioning
More informationINFORMED CONSENT PROCEDURES & WRITING PARTICIPANT INFORMATION AND CONSENT FORMS FOR RESEARCH
OFFICE FOR RESEARCH PROCEDURE INFORMED CONSENT PROCEDURES & WRITING PARTICIPANT INFORMATION AND CONSENT FORMS FOR RESEARCH Purpose: To describe the procedures related to informed consent procedures and
More informationResearch Licence Renewal Inspection Report
Research Licence Renewal Inspection Report Project Title The vitrification of blastocysts following biopsy at the earlycleavage stage or blastocyst stage of embryo development A Pilot Study Research Licence
More informationAUDIT OUTLINE INFORMATION SUMMARY
AUDIT OUTLINE INFORMATION SUMMARY 1. External QA Each DAFNE centre will undergo an external audit visit every 3 years. The external audit visit will take place during a week that the centre being audited
More informationAUDIT TOOL FOR SELF INSPECTION OF COMPLIANCE WITH QUALITY MANAGEMENT SYSTEM FOR PATIENT GROUP DIRECTIONS
AUDIT TOOL FOR DISPENSING SERVICES COMPILED BY: Lynn Morrison ISSUE 1 CHECKED BY: Colette Byrne NUMBER: ISSUE DATE: 01.12.07 SUPERSEDES: NEW REVIEW DATE: 01.12.09 AUDIT TOOL FOR SELF INSPECTION OF COMPLIANCE
More informationStandard Operating Procedure. Selection of studies performed in compliance with Good Laboratory Practice for audit purposes
Scope To describe the procedure for EFSA to request on a yearly or ad-hoc basis the performance of GLP studies audits by the GLP Monitoring Authorities. To lay down criteria for the selection of the GLP
More informationService Level Agreement for the Provision of Level 1 Substance Misuse Services from a Community Pharmacy under contract to NHS Grampian
Service Level Agreement for the Provision of Level 1 Substance Misuse Services from a Community Pharmacy under contract to NHS Grampian 1. Introduction The provision of Substance Misuse (SM) services through
More informationSchool Hearing Screening Policy
School Hearing Screening Policy V2.1 1st August 2017 Page 1 of 13 Table of Contents 1. Introduction... 3 2. Purpose of this Policy... 3 3. Scope... 3 4. Definitions / Glossary... 3 5. Ownership and Responsibilities...
More informationApproval for research carried out on human extracted teeth from Birmingham School of Dentistry Tooth Bank under ethical approval no: 14/EM/2811
Approval for research carried out on human extracted teeth from Birmingham School of Dentistry Tooth Bank under ethical approval no: 14/EM/2811 Generic ethical approval has been obtained for research to
More informationStandard Setting for Accessible Information Advisory Group Meeting 13 August 2015 Minutes
Standard Setting for Accessible Information Advisory Group Meeting 13 August 2015 Minutes Present: Tom Bailey, Research and Policy Officer, Action on Hearing Loss Diane Bullman, Informatics Development
More informationNANDTB-F012 Rev 0 Audit Checklist
NANDTB-F012 Rev 0 Audit Checklist 1. Foreword Minimum Requirements for the Structured Training of Non-Destructive Testing Institutes This document is based upon CEN Technical Report 25108:2006, which is
More informationPolicy for the safe use of oral methotrexate
Policy for the safe use of oral methotrexate Policy Checklist Name of Policy: Purpose of Policy: Directorate responsible for Policy Name & Title of Author: Does this meet criteria of a Policy? Staff side
More informationPOSITION DESCRIPTION TRAINING MANAGER
POSITION DESCRIPTION TRAINING MANAGER August 2015 INTRODUCTION Redspot Car Rentals (RSR) has introduced the position of Training Manager (TM) to help it develop, implement and deliver a national training
More informationTemplate Standard Operating Procedure For: Handling of Midazolam and other controlled drugs in Dental Practices
Name of Dental Practice : Objectives To ensure implementation of the regulations and guidance on safe and secure handling of midazolam and other controlled drugs (CDs) Scope To cover all aspects of obtaining
More informationJob Title Name Signature Date. Director of Nursing Angela Wallace Signed Angela Wallace 30/6/2014
PATIENT GROUP DIRECTIONS FOR SUPPLY OF VARENICLINE (CHAMPIX ) BY AUTHORISED COMMUNITY PHARMACISTS WORKING IN FORTH VALLEY Protocol Number 445 Version 1 Date protocol prepared: June 2014 Date protocol due
More informationNHS BEXLEY CLINICAL COMMISSIONING GROUP GOVERNING BODY FORMAL MEETING 25 th October 2012
ENCLOSURE : C Agenda Item : 160/12 NHS BEXLEY CLINICAL COMMISSIONING GROUP GOVERNING BODY FORMAL MEETING 25 th October 2012 Adult Hearing AQP Action Required : For APPROVAL Executive Summary The procurement
More informationManager. Murray Holt, Head of Operational Support
Policy and Procedure Subject: Issued by: Authorised by: Emergo Train System Issue date: January 2016 Review date: David Nankivell, Health Emergency Planning Murray Holt, Head of Operational Support January2018
More informationNational Lung Cancer Audit outlier policy for Wales 2017
National Lung Cancer Audit outlier policy for Wales 2017 The National Lung Cancer Audit (NLCA) publishes detailed information on the treatment of lung cancer patients, including the outcome of that treatment.
More informationChanging practice to support service delivery
Nurse and Midwife Medicinal Product Prescribing Toolkit Authorised Medicinal Products, Off-label Prescription and Exempt Medicinal Products Toolkit Changing practice to support service delivery Introduction
More informationRITAZAREM. CRF Completion Guidelines
RITAZAREM CRF Completion Trial Title: Protocol Number: An international, open label, randomised controlled trial comparing rituximab with azathioprine as maintenance therapy in relapsing ANCA-associated
More informationProcedural advice on publication of information on withdrawals of applications related to the marketing authorisation of human medicinal products
25 June 2013 rev. 1 1. Procedural advice on publication of information on withdrawals of applications related to the marketing authorisation of human 1 Editorial revisions have been made to the table of
More informationSOUTH EAST COAST AMBULANCE. EPRR Assurance Audit Report
SOUTH EAST COAST AMBULANCE EPRR Assurance Audit Report September 2015 Date Version Author Notes 10.09.15 1 Josh Tarling SECSU Contents Assurance Visit... 3 Audit Details... 3 Areas investigated... 3 Audit
More informationTHE RESPONSIBLE PHARMACIST REGULATIONS
THE RESPONSIBLE PHARMACIST REGULATIONS A SUMMARY OF THE RESPONSES TO PUBLIC CONSULTATION ON PROPOSALS FOR THE CONTENT OF THE REGULATIONS DH INFORMATION READER BOX Policy HR / Workforce Management Planning
More informationPrEP Impact Trial: A Pragmatic Health Technology Assessment of PrEP and Implementation. Part 1
The Elton John Centre Sussex House 1 Abbey Road Brighton BN2 1ES Tel 01273 523079 Fax 01273 523080 PARTICIPANT INFORMATION SHEET AND CONSENT FORM PrEP Impact Trial: A Pragmatic Health Technology Assessment
More informationPolicy: S5 Smoke Free Policy
Policy: S5 Smoke Free Policy Version: S5/15 Ratified by: Trust Management Team Date ratified: 3 rd June 2015 Title of Author: Clinical Services Manager/Specialist & Forensic Title of responsible Executive
More informationGeneric Drug User Fee Amendments of 2012; Regulatory Science Initiatives; Public Hearing;
4160-01-P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration 21 CFR Part 15 [Docket No. FDA-2013-N-0402] Generic Drug User Fee Amendments of 2012; Regulatory Science Initiatives; Public
More informationIPC Athletics Classification Rules and Regulations
IPC Athletics Classification Rules and Regulations February 2013 International Paralympic Committee Adenauerallee 212-214 Tel. +49 228 2097-200 www.paralympic.org 53113 Bonn, Germany Fax +49 228 2097-209
More informationDivision of Research University Policy
Division of Research University Policy SUBJECT: Effective Date: Policy Number: SATELLITE ANIMAL HOUSING FACILITIES June 24, 2016 Supersedes: August 22, 2014 1 5 Responsible Authorities: Vice President,
More informationQuality, Safety and Sourcing in Unlicensed Medicines
Quality, Safety and Sourcing in Unlicensed Medicines with Andrew Trouton Managing Director, UL Medicines Agenda Welcome What is an unlicensed medicine? When should you consider using an unlicensed medicine?
More informationProduct Cost per Pack Cost per 28 days (assuming 2 sprays od) Flixonase years 50mcg in both nostrils od (increasing to max bd prn)
Protocol for Flixonase to Avamys Nasal Spray Switch May 2010 1. Reason Avamys contains the corticosteroid fluticasone furoate (27.5mcg/spray) and Flixonase nasal spray contains fluticasone propionate (50mcg/spray).
More informationSeretide 250mcg/125mcg Evohaler switch to Fostair 100/6 MDI in COPD.
Seretide 250mcg/125mcg Evohaler switch to Fostair 100/6 MDI in COPD. Applies to HaRD CCG employed Pharmacists and Medicines Optimisation Technicians These protocols are produced by the NY&AWC MM team hosted
More informationCreating a Smoke Free Workplace Policy
Creating a Smoke Free Workplace Policy Solent NHS Trust policies can only be considered to be valid and up-to-date if viewed on the intranet. Please visit the intranet for the latest version. Purpose of
More informationBMA INFORMATION BULLETIN No. 23. International Safety Management (ISM) Code
BMA INFORMATION BULLETIN No. 23 International Safety Management (ISM) Code Guidance and instructions for Ship-owners, Managers, Masters, Bahamas Recognised Organisations and Bahamas Approved Inspectors
More informationabcdefghijklmnopqrstu
1P P Floor NHS: PCA(D)(2010)6 Primary and Community Care Directorate Primary Care Division abcdefghijklmnopqrstu Dear Colleague GENERAL DENTAL SERVICES 1. Clinical Audit Arrangements 1 August 2010 2. Listing
More informationNorth of England Cancer Network. Policies and Procedures. Standards for the Safe Use of Oral Anticancer Medicines
\ North of England Cancer Network Policies and Procedures Standards for the Safe Use of Oral Anticancer Medicines NECN Oral Anticancer medicine Policy version 1.6 Page 1 of 17 Issue Date: Feb 2017 Contents
More informationEXECUTIVE SUMMARY. Purpose
EXECUTIVE SUMMARY REPORT TO: Trust Board DATE: Tuesday 4 December 2018 AGENDA NO: 2.1 AGENDA ITEM: Healthcare Worker Flu Vaccination Best Practice SPONSOR: Julie Cooper, Director of People PREPARED BY:
More informationDarwin Marine Supply Base HSEQ Quality Management Plan
Darwin Marine Supply Base HSEQ Quality Management Plan REVISION SUMMARY Revision Date Comment Authorised 0 29.9.13 Initial input JC 1 12.1.15 General Review JC 2 3 4 5 6 7 8 9 Revision Log Revision No
More informationPolicy for the Development and Control of Patient Group Directions (PGDs)
Policy for the Development and Control of Patient Group Directions (PGDs) Reference No: P_CIG_13 Version: 4 Ratified by: LCHS Trust Board Date ratified: 8 May 2018 Name of originator/author: Name of responsible
More information2.2 The primary roles and responsibilities of the Committee are to:
Edinburgh Child Protection Constitution 1. Introduction 1.1 This document sets out the governance arrangements established to promote the delivery of integrated, high quality child protection services
More informationIT and Information Acceptable Use Policy
BMI IMpol04 Information Management IT and Information Acceptable Use Policy This is a controlled document and whilst this document may be printed, the electronic version posted on the intranet/shared drive
More informationPOLICY FOR CLINICAL AUDIT OF NEW CASES OF INVASIVE CERVICAL CANCER AND DISCLOSURE OF RESULTS
POLICY FOR CLINICAL AUDIT OF NEW CASES OF INVASIVE CERVICAL CANCER AND DISCLOSURE OF RESULTS Reference Number Version: Status Author: Alison Cropper CL-CP/2009/010 V3 Final Job Title: Hospital Based Programme
More informationDeveloped By Name Signature Date
Patient Group Direction 2156 version 2.0 Administration of Ipratropium 250mcg/ml Nebuliser Solution in Acute Asthma by Registered Practitioners employed by Torbay and South Devon NHS Foundation Date of
More informationSection 32: BIMM Institute Student Disciplinary Procedure
Section 32: BIMM Institute Student Disciplinary Procedure Introduction Academic Development & Quality Assurance Manual This Student Disciplinary Procedure provides a framework for the regulation of BIMM
More informationPROFICIENCY TESTING POLICY
Supersedes Prepared by: APPROVALS in this section Approved by: Date: Laboratory Director RECORD OF REVIEWS Date Signature Title Procedural Changes/Review VERSION HISTORY Revision # 0 Section #/Changes
More informationADMINISTRATION OF INSULIN
STANDARD OPERATING PROCEDURE ADMINISTRATION OF INSULIN Issue History First issued April 2012 Issue Version Two Purpose of Issue/Description of Change Planned Review Date To promote the safe administration
More informationInternational Standard for Athlete Evaluation. July 2015
International Standard for Athlete Evaluation July 2015 International Paralympic Committee Adenauerallee 212-214 Tel. +49 228 2097-200 www.paralympic.org 53113 Bonn, Germany Fax +49 228 2097-209 info@paralympic.org
More informationWCPT Subgroups. Information Pack: September 2011
WCPT Subgroups Information Pack: 1. Background... 2 2. Requirements for WCPT subgroups... 3 3. Duties of WCPT subgroups... 3 4. Rights of WCPT Subgroups... 4 5. WCPT website... 4 6. Applications... 4 7.
More information